Julie Ledgerwood

Ledgerwood leads clinical trials and clinical collaborations for the VRC; and has served as principal investigator, protocol chair, or associate investigator for over 60 Phase 1-2b clinical trials studying vaccines and monoclonal antibodies targeting pathogens such as HIV, influenza, Ebola, malaria, Chikungunya, and Zika in over 13 countries. She led the first human trial aimed at testing a vaccine for Ebola virus and the first evaluation of mAb114, a monoclonal antibody targeting Ebola.
For the past 15 years, she has conducted research with numerous academic research teams and has led international vaccine research collaborations. Ledgerwood has authored textbook chapters and over 85 publications in peer-reviewed journals. Provided by Wikipedia